Tarsus Pharmaceuticals (TARS) News Today → This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad) Free TARS Stock Alerts $38.73 +0.49 (+1.28%) (As of 05:19 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 4:18 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 3.6%May 17 at 1:54 PM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 3.6%Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 3.6%May 15, 2024 | americanbankingnews.comHC Wainwright Comments on Tarsus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:TARS)May 15, 2024 | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Given New $61.00 Price Target at HC WainwrightMay 13, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $61.00HC Wainwright raised their price objective on shares of Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the company a "buy" rating in a research report on Monday.May 13, 2024 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from BrokeragesMay 13, 2024 | americanbankingnews.comWilliam Blair Comments on Tarsus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:TARS)May 13, 2024 | americanbankingnews.comTarsus Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($1.10) Per Share, Lifesci Capital Forecasts (NASDAQ:TARS)May 12, 2024 | finance.yahoo.comEarnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their EstimatesMay 12, 2024 | americanbankingnews.comBarclays Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $60.00May 12, 2024 | americanbankingnews.comOppenheimer Raises Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61.00May 11, 2024 | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading 5.8% Higher After Analyst UpgradeMay 10, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Given New $60.00 Price Target at BarclaysBarclays increased their target price on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an "overweight" rating in a report on Friday.May 10, 2024 | finance.yahoo.comTarsus Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | markets.businessinsider.comAnalyst Ratings For Tarsus PharmaceuticalsMay 9, 2024 | globenewswire.comTarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare ConferenceMay 9, 2024 | finanznachrichten.deTarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 9, 2024 | msn.comTarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71MMay 9, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High at $42.50Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 12-Month High at $42.50May 9, 2024 | marketbeat.comVivo Capital LLC Has $36.13 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Vivo Capital LLC decreased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,784,006 shares of the company's stock aftMay 9, 2024 | finance.yahoo.comTarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | investorplace.comTARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comTarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 7, 2024 | markets.businessinsider.comTarsus Pharmaceuticals earnings: here's what Wall Street expectsMay 2, 2024 | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on WednesdayTarsus Pharmaceuticals (NASDAQ:TARS) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | globenewswire.comTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024May 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)April 30, 2024 | marketbeat.comabrdn plc Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)abrdn plc acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 72,032 shares of the company's stock, valued at approximately $1,459,000April 28, 2024 | latimes.comMaáza MartinApril 27, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Vivo Capital LLCVivo Capital LLC trimmed its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 68.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 565,550 shares of the company's stock after selling 1,2April 25, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)April 24, 2024 | lse.co.ukBioPharma Credit to loan USD100 million to Tarsus PharmaceuticalsApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tarsus Pharmaceuticals Amidst Strategic Debt Refinancing and Strong Financial OutlookApril 23, 2024 | globenewswire.comTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonApril 20, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Holdings Trimmed by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 23.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 187,414 sharApril 19, 2024 | finance.yahoo.comInsider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%April 19, 2024 | marketbeat.comQ1 2024 EPS Estimates for Tarsus Pharmaceuticals, Inc. Boosted by Analyst (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at William Blair lifted their Q1 2024 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the company will post earnings oApril 13, 2024 | marketbeat.comVanguard Group Inc. Has $27.58 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 25.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,551,802 shares of the company's stock after buying an additional 316,128 shares during the pApril 12, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.2%Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.2%April 11, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.1%Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.1% HigherApril 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should KnowApril 6, 2024 | msn.comScientists share trial results for new tick-repelling drug for humans: 'An amazing opportunity'March 28, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.3%Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 6.3%March 21, 2024 | investing.comTarsus Pharmaceuticals executive sells over $130k in company stockMarch 21, 2024 | investing.comTarsus Pharmaceuticals exec sells over $135k in stockMarch 20, 2024 | insidertrades.comBryan Wahl Sells 4,436 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 19, 2024 | marketbeat.comInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells 4,436 Shares of StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares of the company's stock, valued at approximately $1,253,100.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 18, 2024 | msn.comPill Targeting Tick-Induced Lyme Disease Shows Promise in Human TrialsMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 17.500 put Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Digitizing the $11T commodities sector with one tiny stock (Ad)One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. It’s an opportunity that likely won’t stay at these levels for long TARS Media Mentions By Week TARS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.820.42▲Average Medical News Sentiment TARS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼113▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vir Biotechnology News Neumora Therapeutics News 4D Molecular Therapeutics News Cullinan Oncology News Scholar Rock News BioCryst Pharmaceuticals News Inhibrx News Autolus Therapeutics News CG Oncology News Fusion Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
